Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > ORGANIZATION
ORGANIZATION
- Drug Wholesalers Post Virtually Flat Sales in FY2017: JPWA
August 10, 2018
- Total No. of Sales Reps Shrinks for 4 Years in a Row at 62,433: Survey
July 27, 2018
- Generic Use Rate at 74.1% in January-March: JGA
July 4, 2018
- Yokokura Wins 4th Term to Lead Japan Medical Association
June 25, 2018
- Expand Exemption Criteria in New Off-Patent Price Cut Rule: Japan Pharma Lobby
June 19, 2018
- Japan Pharma Group Calls for Careful Approach on PMP Deduction for Comparator Drugs
June 19, 2018
- Don’t Make Coverage Decision on CEA, Tweak Prices with Limited Scope: FPMAJ
June 18, 2018
- Scrap Unfair Company Criteria for Price Maintenance Premium: Japan Trade Group
June 18, 2018
- FPMAJ Welcomes Chuikyo’s Openness to Views of Experts on CEA: Drug Pricing Committee Chair
June 18, 2018
- Atsushi Kamide of Astellas Elected as New Chairman of FPMAJ’s Drug Pricing Committee
June 18, 2018
- Hiroki Nakatani Named as New Board Chair for GHIT Fund
June 8, 2018
- JPMA Proposes Creation of Disease Registry to Employ Medical Data
June 5, 2018
- New JPMA Chief Calls for Scrapping PMP Company Criteria
June 1, 2018
- Sawai President Elected New Generic Industry Chief
May 30, 2018
- Drug Damage Watchdog Submits Opinion to Health Ministry, Opposing Current Conditional Early Approval System
May 30, 2018
- Big Data Analysis Finds Low Generic Drug Use Rate among Healthcare Professionals: Kyokai Kenpo
May 28, 2018
- Daiichi Sankyo CEO Nakayama Appointed as New President of JPMA
May 25, 2018
- Isao Teshirogi Elected New FPMAJ Chairman
May 25, 2018
- PhRMA Vision Report Stresses Innovation as Investment for Healthier Lifespans
May 17, 2018
- Over 80% Concerned about Restrictions on Access to Prescription Drugs: PhRMA Survey
May 15, 2018
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…